The present invention relates to a composition for treating hair loss or promoting hair growth which contains a silk protein, and plasma or serum components. According to the present invention, due to the synergistic effect of a silk protein and plasma or serum components, the effect of promoting hair growth and the effect of treating hair loss can be expected to be more efficient.

A method for treating a cerebrovascular disease according to an embodiment of the present disclosure includes administering a composition comprising at least one of melittin and magnetic iron oxide nanoparticle loaded with melittin as an effective component to a subject in need thereof. A composition according to an embodiment of the present disclosure for preventing, ameliorating, or treating a cerebrovascular disease includes melittin or magnetic iron oxide nanoparticle loaded with melittin as an effective component. The melittin or magnetic iron oxide nanoparticle loaded with melittin not only can reduce the diameter of cerebral arteries, increase the thickness of cerebral arteries, increase the content of elastin and smooth muscles, and reduce the content of abnormal collagen but also has an effect of suppressing the expression of the factors which mediate an inflammatory response.

The present invention relates to a peptide derived from the defensin-3 from the red flour beetle Tribolium castaneum, to pharmaceutical compositions containing same, and to the use thereof as an antimicrobial in the treatment of infections caused by gram-positive bacteria, gram-negative bacteria and fungi. The invention also relates to the use of the peptide and pharmaceutical compositions containing same, in the treatment of cancer, particularly breast cancer. The compound described is a peptide derived from defensin-3 from the red flour beetle T. castaneum.

A composition includes aluminum hydroxide gel and a conjugate of at least one CysA13(33-40) peptide linked to the keyhole limpet hemocyanin (KLH). Maleimidobutyric acid Nhydroxysuccinimide ester (SM) serves as cross-linking agent. The composition can produce an effective and specific immune response against Aβ40. The antibodies produced are specific for Aβ40 without significantly binding to Aβ42. The composition can increase the response against Aβ40 compared with the response produced by other conjugates that include CysAβ(33-40) peptide and KLH, and are bound or conjugated by other crosslinking agents.

55139597

Nutritive polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides, vectors for expressing the polypeptides, methods of making the polypeptides using recombinant microorganisms, compositions and formulations that comprise the polypeptides, and methods of using the polypeptides, compositions and formulations.

The invention relates to novel Evasin polypeptides with novel chemokine-binding properties and their use in inhibiting chemokines or detecting chemokine expression and inflammation.

CNS metastases are a major cause of cancer deaths with few therapeutic options for treatment. Monoclonal anti-body-based therapy is one of the most successful therapeutic strategies for cancer; however, its efficacy is limited against CNS metastases due to insufficient CNS delivery. Here, we show significantly improved antibody delivery to the CNS using novel timed-release nanocapsules that encapsulate individual antibodies within a crosslinked phosphorylcholine polymer and gradually release cargo through hydrolysable crosslinkers. A single course of rituximab (RTX) nanocapsule treatment elevates RTX levels in the CNS by nearly 10-fold compared to native RTX. We improved control of CNS metastases in a murine xenograft model of non-Hodgkin lymphoma; moreover, using a xenograft humanized BLT mouse model, lymphomas were eliminated with a single course of RTX nanocapsule treatment. This approach is useful for treatment of cancers with CNS metastases and is generalizable for delivery of any antibody to the CNS.

The present invention relates to a fusion polypeptide that inhibits TLR1/2, TLR2/6, TLR7, TLR8 and TLR9 signaling pathways as well as Toll-like receptor 4 (TLR4) and TLR3, and a pharmaceutical composition for preventing or treating TLR pathway mediated diseases. The fusion peptide of the present invention has an excellent effect of inhibiting TLR4 and various TLR pathways and can be effectively used in preventing and treating various TLR pathway mediated diseases caused by the signaling pathways, such as autoimmune diseases, inflammatory diseases and degenerative neurological diseases, by inhibiting the TLR mediated immune responses.

Provided are methods and compositions relating to a dental composition more specifically to prepare the damaged dentin of the tooth for animals and pets such as canine, feline and members of the taxonomic family Equidae prior to repair. The dental compositions include a bioactive glass and a non-aqueous solvent comprising an alcohol, anti-inflammatory and anti-pain reliever.

A system, including methods and compositions, for treatment of ischemia.